Investigation of the Relationship Between Salivary Histatine-5 Level and Vaginal Candidiasis in Women
The low Histatine-5 (HST-5) level of the saliva can lead to vaginal candidiasis. Because HST-5 level in the saliva can effect vaginal Ph, flora and local defence mechanisms.
Histatine-5 is secreted in the parotis and submandibular glands. İt riches histidine amino ascid and have antifungal activity. Salivary proteins and their plasma levels were found as similar in the literature.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Women with regularly menstrual cycle will enroll in the study than will separate two groups:
Study group: women with vaginal candidiasis ( diagnosed by clinic and lab.)
Control group: women ( not have any vaginal infections candida and others)
Saliva samples will be taken from two groups than HST-5 level will be analyzed. Finally HST-5 levels of the two groups will be compared .
Women with diabetes, immun deficiency, pregnancy, virgin, menopausal period , premature ovarian failure will be excluded.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Usak, Turkey
- İrem Şenyuva
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria: women with regularly menstrual cycle , diagnosed candidal vaginosis and not have any vaginal infection.
-
Exclusion Criteria: diabetes, immun deficiency, menopause, premature ovarian failure, pregnancy, virgin
-
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Case group
vaginal candidiasis
|
salivary sample
|
|
Control group
healty women
|
salivary sample
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SALIVARY HISTATINE-5 LEVEL IN THE WOMEN WITH VAGINAL CANDIDIASIS
Time Frame: 1 month
|
we done salivary protein electrophoresis( as a small sample group ; consist of vaginal candidiasis and control patients) and Hst5 protein band was seen
|
1 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SALIVARY HISTATINE-5 LEVEL IN THE WOMEN WITH VAGINAL CANDIDIASIS
Time Frame: 2 month
|
We found , low salivary Hst5 levels in women with vaginal candidiasis than control group (p=0.001)
|
2 month
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: İREM ŞENYUVA, M.D, Uşak Training and Research Hospital
Publications and helpful links
General Publications
- Khurshid Z, Najeeb S, Mali M, Moin SF, Raza SQ, Zohaib S, Sefat F, Zafar MS. Histatin peptides: Pharmacological functions and their applications in dentistry. Saudi Pharm J. 2017 Jan;25(1):25-31. doi: 10.1016/j.jsps.2016.04.027. Epub 2016 May 4.
- Loo JA, Yan W, Ramachandran P, Wong DT. Comparative human salivary and plasma proteomes. J Dent Res. 2010 Oct;89(10):1016-23. doi: 10.1177/0022034510380414. Epub 2010 Aug 25.
- Liao H, Liu S, Wang H, Su H, Liu Z. Efficacy of Histatin5 in a murine model of vulvovaginal candidiasis caused by Candida albicans. Pathog Dis. 2017 Aug 31;75(6). doi: 10.1093/femspd/ftx072.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Usak State Hospital
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Candidiasis
-
NCT01869829CompletedPediatric Invasive Candidiasis
-
NCT00786903CompletedInvasive Candidiasis | Pulmonary Candidiasis
-
NCT02333448Completed
-
NCT00608335CompletedCandidemia | Invasive Candidiasis | Esophageal Candidiasis | Oropharyngeal Candidiasis
-
NCT00607763CompletedCandidemia | Invasive Candidiasis | Esophageal Candidiasis | Oropharyngeal Candidiasis
-
NCT02801682CompletedInvasive Candidiasis
-
NCT03906916Terminated
-
NCT01666769CompletedInvasive Candidiasis
-
NCT00672841Completed
Clinical Trials on salivary sample
-
NCT04261803CompletedHyperlipoproteinemia Type II
-
NCT04183023Active, not recruitingGenetics, Population
-
NCT06262152RecruitingBlindness | Agenesis of Corpus Callosum | Septo-Optic Dysplasia
-
NCT05352841RecruitingEarly Childhood Caries
-
NCT02505828CompletedJuvenile Idiopathic Arthritis | Septic Arthritis
-
NCT04913545Completed
-
NCT01590043UnknownInflammatory Bowel Diseases
-
NCT01675258UnknownGastric Cancer | Pancreatic Cancer | Colorectal Cancer and Pre-cancer Polyps
-
NCT04848870Recruiting
-
NCT06072820WithdrawnEndometriosis | Diagnosis